Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsing Multiple Sclerosis (RMS)”

88 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 88 results

Not applicableStudy completedNCT06251986
What this trial is testing

A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice

Who this might be right for
Relapsing Forms of Multiple Sclerosis
Novartis Pharmaceuticals 310
Testing effectiveness (Phase 2)Temporarily pausedNCT04909502
What this trial is testing

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis

Who this might be right for
Relapsing Forms of Multiple Sclerosis
Emerald Health Pharmaceuticals 50
Post-approval studies (Phase 4)Study completedNCT04869358
What this trial is testing

Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab

Who this might be right for
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals 34
Large-scale testing (Phase 3)Active Not RecruitingNCT04926818
What this trial is testing

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis (MS)
Novartis Pharmaceuticals 129
Large-scale testing (Phase 3)Ended earlyNCT04032171
What this trial is testing

Study of Evobrutinib in Participants With RMS

Who this might be right for
Relapsing-remitting Multiple Sclerosis
EMD Serono Research & Development Institute, Inc. 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT05119569
What this trial is testing

Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

Who this might be right for
Relapsing Multiple Sclerosis
Hoffmann-La Roche 109
Large-scale testing (Phase 3)Active Not RecruitingNCT05147220
What this trial is testing

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

Who this might be right for
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals 1,000
Large-scale testing (Phase 3)Active Not RecruitingNCT07211633
What this trial is testing

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

Who this might be right for
Relapsing Multiple Sclerosis
TG Therapeutics, Inc. 360
Post-approval studies (Phase 4)Study completedNCT01895335
What this trial is testing

Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients

Who this might be right for
Multiple Sclerosis
Sanofi 1,001
Testing effectiveness (Phase 2)Study completedNCT03560739
What this trial is testing

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals 284
Post-approval studies (Phase 4)Active Not RecruitingNCT06396039
What this trial is testing

Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

Who this might be right for
Relapsing Multiple Sclerosis
Bristol-Myers Squibb 84
Not applicableStudy completedNCT02921035
What this trial is testing

Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

Who this might be right for
Relapsing Multiple Sclerosis (RMS)
Merck KGaA, Darmstadt, Germany 594
Large-scale testing (Phase 3)Study completedNCT04788615
What this trial is testing

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals 185
Early research (Phase 1)Study completedNCT02797015
What this trial is testing

Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

Who this might be right for
Multiple Sclerosis
Celgene 22
Early research (Phase 1)Study completedNCT01884935
What this trial is testing

PK and PD Study of Natalizumab in Pediatric Subjects With RRMS

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 13
Large-scale testing (Phase 3)Study completedNCT04626921
What this trial is testing

A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

Who this might be right for
Relapsing Multiple Sclerosis
Clene Nanomedicine 55
Large-scale testing (Phase 3)Study completedNCT04121221
What this trial is testing

Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Mapi Pharma Ltd. 1,016
Early research (Phase 1)Active Not RecruitingNCT06220201
What this trial is testing

Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Who this might be right for
Multiple SclerosisMyasthenia Gravis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT06617793
What this trial is testing

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

Who this might be right for
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals 28
Large-scale testing (Phase 3)Looking for participantsNCT06846281
What this trial is testing

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Who this might be right for
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals 400
Next Page